Business
AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board
AXIM Biotechnologies Appoints Clinical Research and DED Expert Dr. Michael E. Stern to its Medical Advisory Board.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and Dry Eye Disease (DED) diagnostics, today announced it has appointed Michael E. Stern, MS, Ph.D., to its Medical Advisory Board. He joins AXIM’s four other Advisory Board members including Drs. Kelly K. Nichols, Henry D. Perry, Laura Periman, and its Chairman Joseph Tauber. Dr. Stern brings over 30 years of senior scientific, research, academic and executive level expertise with Dry Eye Disease and Ocular Surface Disease (OSD). Currently, he is a Principal and Chief Science Officer for immunEyze, a boutique contract research organization that performs preclinical and clinical research for OSD indications. Previously, he served for 26 years with Allergan where he rose to Principal Scientist and Vice-President Inflammation Research whose work included elucidating the pathophysiology of DED. He is extensively published in leading ocular journals. “Our Medical Advisory Board just keeps getting better,” said John W. Huemoeller II, AXIM® Biotech Chief Executive Officer. “Michael is a highly regarded scientific professional in Dry Eye Disease as well as OSD. His three decades of experience leading laboratory research for big and small companies, combined with his extensive academic experience and connections will serve Axim well as we prepare to commercialize our two FDA-approved DED diagnostic tests. “In addition to its US focus, AXIM has global ambitions for its DED diagnostic portfolio and I like that Dr. Stern serves as Co-Director of Ocular Immunology at IOBA in Spain, and Visiting Professor of Ophthalmology at the University of Cologne -- as he brings relationships and insight into the European marketplace. I’m delighted to welcome Michael to the Advisory Board.”   Michael E. Stern, MS, Ph.D. Summary BioDr. Stern currently serves as Chief Science officer for immunEyze, a boutique contract research organization that performs preclinical and clinical research for OSD. Previously, he served for 26 years with Allergan where he rose to Principal Scientist and Vice-President Inflammation Research whose work includes elucidating ...